CD19+ and CD 22+ B-ALL
1 clinical trials · Condition
◉ Watch CD19+ and CD 22+ B-ALL
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia (NCT05225831) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-08-15 |
Track CD19+ and CD 22+ B-ALL automatically
Every clearance here is in the API, with alerts when new ones post.